ORKA Chief Medical Officer Goncalves Joana Sells $524K of Stock

Joana Goncalves, the Chief Medical Officer of Oruka Therapeutics, Inc. (NasdaqGM: ORKA), sold 7,000 shares on October 15, 2026, for a total value of approximately $523,648. This transaction was planned in advance, and the shares were sold at an average price of $74.81 each.

Inside Goncalves's Trade

Goncalves's sale adds to a series of insider transactions at Oruka. This sale comes shortly after other insiders, including General Counsel Paul Quinlan and Senior Vice President Arjun Agarwal, also sold shares in planned transactions. The recent trades show that insiders are adjusting their holdings amid market conditions.

Other Institutional Activity in Oruka

Several institutional investors have also shown interest in Oruka Therapeutics. FMR, LLC increased its stake by 1,626,036 shares, bringing its total to 9,057,645 shares valued at about $651.5 million. Blackrock Inc. added 1,463,053 shares, raising its holdings to 4,990,181 shares worth approximately $358.9 million. Capital World Investors grew its position by 1,700,820 shares, ending with 3,401,639 shares valued at around $244.7 million.

Oruka Therapeutics, Inc. Stock Down 1.3%

As of October 16, 2026, Oruka Therapeutics shares are trading around $72.91, which is below its 50-day moving average of $93.10. The stock is also below its 52-week high of $115.52, indicating a significant drop from earlier highs. However, it remains above its 52-week low of $25.11, suggesting some resilience in the market.

Recent Earnings

Oruka Therapeutics reported a trailing twelve-month revenue of $0, reflecting its status as a clinical-stage biopharmaceutical company focused on developing treatments for psoriasis and other conditions. The next earnings report is scheduled for November 11, 2026.

Insider Buying and Selling at Oruka Therapeutics, Inc.

In addition to Goncalves's recent sale, several other insiders have sold shares of Oruka Therapeutics. On June 15, 2026, CEO Klein Lawrence Otto sold 1,729 shares at an average price of $69.69, totaling about $120,494. On the same day, General Counsel Paul Quinlan sold 733 shares, also at $69.69, valued at approximately $51,083. Earlier, on September 21, 2026, Quinlan sold 10,000 shares at an average price of $93.64, worth about $936,417.

Analysts Set New Price Targets

Analysts have reiterated their positive outlook on Oruka Therapeutics. On August 11, 2026, Guggenheim maintained a Buy rating with a price target of $200. Wedbush also reiterated an Outperform rating, setting a target of $165. HC Wainwright & Co. confirmed a Buy rating with a target of $120 on September 3, 2026. The consensus among analysts is a strong buy with a mean price target of $155.00.

About Oruka Therapeutics

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California. The company focuses on developing innovative monoclonal antibody therapies for inflammatory and immunological conditions, particularly psoriasis. Its lead products are currently in various stages of clinical trials, aiming to address significant unmet medical needs.

Bottom Line

Goncalves's recent sale is part of a broader trend of insider trading at Oruka, as several executives have sold shares in recent weeks. Investors should keep an eye on the upcoming earnings report on November 11, 2026, and continue to monitor insider activity and analyst ratings for further insights into the company's direction.